Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
GlobalData on MSN13d
Daiichi Sankyo doses first subject in Phase III AML therapy trialDaiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...
She initially received oral tretinoin (Vesanoid) followed by daunorubicin on days 1 through 3 and cytarabine on days 1 to 5 (planned treatment is to receive cytarabine for 2 more doses).
However, treating patients with bendamustine/rituximab plus acalabrutinib might be preferred to either option with cytarabine. Although the results showed that the bendamustine/rituximab plus ...
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback